UK regulator approves Pfizer’s hair loss drug

Pfizer logo

UK regulator approves Pfizer’s hair loss drug

Nov 1 (Reuters) – Britain’s medicines regulator on Wednesday approved Pfizer Inc’s (PFE.N) drug to treat hair loss caused by an autoimmune disease.

The drug, branded as Litfulo, has been approved by UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for people aged 12 years and older suffering from severe alopecia areata.

It has already been approved for use in Europe and the United States.

Alopecia areata is a condition where the immune system attacks hair follicles and causes hair to fall out, often in clumps.

Reporting by Eva Mathews in Bengaluru; Editing by Shilpi Majumdar

Source: Reuters

/by
You might also like
Japan, commuters, COVID-19Japan’s Daiichi Sankyo gets approval for COVID vaccine, first for country
PfizerPfizer starts late-stage trial of mRNA-based flu vaccine
FDAFDA approves first gene therapy for high-risk, non-muscle-invasive bladder cancer
Novartis, CaliforniaNovartis wins first FDA approval for oral monotherapy for rare blood disorder
syringesUS CDC contemplates who should get the new COVID shots
Eli LillyNovo, Lilly rivals explore booming weight-loss drug market entry
European Union flagEU regulator backs gene therapy to treat rare bleeding disorder
SanofiSanofi, Sobi score FDA nod for second hemophilia A treatment